Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer

Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer

Background and objective It has been proven that epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) significantly benefits advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations in progression-free survival time with better tolerance. This study is undertake...

Full description

Bibliographic Details
Main Authors: Jianjie LI, Lili QU, Xing Wei, Hongjun GAO, Weixia WANG, Haifeng QIN, Chuanhao TANG, Wanfeng GUO, Hong WANG, Xiaoqing LIU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2012-05-01
Series:Chinese Journal of Lung Cancer
Subjects:
Lung neoplasms
Epidermal growth factor receptor
Tyrosine kinase inhibitor
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2012.05.09

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2012.05.09

Similar Items